Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Our in silico analysis of cancer gene expression profiling and transcriptome sequencing we revealed an overexpression of GLYATL1 in primary prostate cancer.
|
31376196 |
2019 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Our in silico analysis of cancer gene expression profiling and transcriptome sequencing we revealed an overexpression of GLYATL1 in primary prostate cancer.
|
31376196 |
2019 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
p300/CBP Associated Factor (PCAF), a GNAT family member protein, represent a valid target for therapeutic interventions since its dysfunction has implicated in variety of diseases like cancer, diabetes, inflammatory diseases, etc.
|
30118769 |
2018 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
p300/CBP Associated Factor (PCAF), a GNAT family member protein, represent a valid target for therapeutic interventions since its dysfunction has implicated in variety of diseases like cancer, diabetes, inflammatory diseases, etc.
|
30118769 |
2018 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Low-grade cancers had higher GLYATL1 expression compared to high-grade prostate tumors.
|
31376196 |
2019 |
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Confirming these findings by immunohistochemistry, we show that GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue.
|
31376196 |
2019 |
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Confirming these findings by immunohistochemistry, we show that GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue.
|
31376196 |
2019 |
Metastatic Prostate Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Confirming these findings by immunohistochemistry, we show that GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue.
|
31376196 |
2019 |
Metastasis from malignant tumor of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Confirming these findings by immunohistochemistry, we show that GLYATL1 is overexpressed in primary prostate cancer compared with metastatic prostate cancer and benign prostatic tissue.
|
31376196 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This protein belongs to the GNAT GCN5 family and shows proapoptotic activity in human hepatocellular carcinoma cells.
|
24248912 |
2013 |
Developmental Disabilities
|
0.010 |
Biomarker
|
group |
BEFREE |
The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders.
|
11437234 |
2001 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders.
|
11437234 |
2001 |